RenovoRx, Inc. (RNXT) News
Track canonical SquawkNews coverage tagged to RNXT, RenovoRx, Inc.. This hub brings together deduplicated headlines about alpaca us equities, markets catalysts, earnings, analyst actions, and wider market events so traders can review how a developing story changed over time. It contains 11 indexed stories across 9 publication days and is ordered by the same first-publication timeline used by LiveCast.
H
RNXT: RenovoCath's commercial and clinical momentum accelerates with strong survival data and expanding adoption
RenovoCath's targeted drug delivery system is gaining rapid commercial traction, now in 21 centers with plans to exceed 35 by year-end. Interim phase III data show a six-month survival benefit and 65% reduction in toxici
EARNINGS | Sep 14, 2026, 08:06 PM UTC
H
RNXT: RenovoCath's device shows strong adoption, survival benefit, and reduced toxicities in pancreatic cancer
RenovoCath's proprietary delivery system is driving rapid commercial adoption, with 21 centers active and a $400 million market opportunity. Interim phase III data show a 6-month survival benefit and 65% reduction in tox
EARNINGS | Sep 14, 2026, 07:42 PM UTC
L
RNXT jumps to 52-week high amid biotech strength
RNXT shares rose to a 52-week high, +15%. Other biotech names cited: EOLS, CRNX, APGE.
EQUITY | Sep 01, 2026, 08:01 AM UTC
L
Ascendiant Capital raises RenovoRx price target to $14.50
Ascendiant Capital raised its RenovoRx price target to $14.50/share from $14.00/share.
EQUITY | Aug 28, 2026, 11:00 AM UTC
L
RenovoRx RNXT highlights peer-reviewed PK/PD data for TAMP targeting
RenovoRx (RNXT) highlights a peer-reviewed publication presenting pharmacokinetic and pharmacodynamic (PK/PD) data supporting its TAMP™ targeted drug-delivery platform in locally advanced pancreatic cancer.
EQUITY | Aug 25, 2026, 12:30 PM UTC
M
RenovoRx regains Nasdaq minimum bid price compliance
RenovoRx says it has regained compliance with Nasdaq’s minimum bid price requirement for RNXT.
REGULATION | Aug 21, 2026, 12:30 PM UTC
M
RenovoRx gets U.S. patent allowance notice for RenovoCath® catheter
RenovoRx (RNXT) receives a notice of allowance for a new U.S. patent covering RenovoCath®, an advanced dual-occlusion catheter for targeted therapeutic drug-delivery in cancer treatment.
REGULATION | Aug 20, 2026, 12:31 PM UTC
L
RenovoRx Raises FY2026 Sales Guidance
RenovoRx raises FY2026 sales outlook to $3.750M-$4.250M
EARNINGS | Aug 12, 2026, 08:15 PM UTC
L
RNXT Reports Record Q2 2026 Results
RNXT reports record second quarter 2026 results with 61% sequential revenue growth
EARNINGS | Aug 12, 2026, 08:05 PM UTC
M
RenovoRx Expands RenovoCath Use To Solid Tumors
RenovoRx expands use of RenovoCath to solid tumors
EQUITY | Aug 06, 2026, 12:31 PM UTC
L
RNXT - RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET - Click
RNXT - RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET
EARNINGS | Jul 29, 2026, 12:30 PM UTC